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Summary
Mutations resulting in defective splicing constitute a sig-
nificant proportion (30/62 [48%]) of a new series of
mutations in the ATM gene in patients with ataxia-tel-
angiectasia (AT) that were detected by the protein-trun-
cation assay followed by sequence analysis of genomic
DNA. Fewer than half of the splicing mutations involved
the canonical AG splice-acceptor site or GT splice-donor
site. A higher percentage of mutations occurred at less
stringently conserved sites, including silent mutations of
the last nucleotide of exons, mutations in nucleotides
other than the conserved AG and GT in the consensus
splice sites, and creation of splice-acceptor or splice-do-
nor sites in either introns or exons. These splicing mu-
tations led to a variety of consequences, including exon
skipping and, to a lesser degree, intron retention, acti-
vation of cryptic splice sites, or creation of new splice
sites. In addition, 5 of 12 nonsense mutations and 1
missense mutation were associated with deletion in the
cDNA of the exons in which the mutations occurred.
No ATM protein was detected by western blotting in
any AT cell line in which splicing mutations were iden-
tified. Several cases of exon skipping in both normal
controls and patients for whom no underlying defect
could be found in genomic DNA were also observed,
suggesting caution in the interpretation of exon deletions
observed in ATM cDNA when there is no accompanying
identification of genomic mutations.
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Introduction
Ataxia-telangiectasia (AT [MIM 208900]) is an auto-
somal recessive disorder with a diverse phenotype that
includes progressive cerebellar ataxia, oculocutaneous
telangiectasias, radiation hypersensitivity, increased can-
cer incidence, immunodeficiency, chromosome instabil-
ity, and elevated levels of serum alpha-fetoprotein (re-
viewed in Gatti 1991, 1998). Genetic studies of families
with AT indicate that heterozygous carriers for AT, al-
though generally asymptomatic, have an increased risk
for the development of breast cancer (Swift et al. 1991;
Athma et al. 1996). The gene mutated in AT, ATM, was
identified in 1995 (Savitsky et al. 1995a, 1995b; Uziel
et al. 1996). In light of both the public-health implica-
tions of the reported cancer risk in known AT carriers
and estimates that place their population frequency at
0.5%–1%, there is substantial interest in detection and
characterization of mutations in ATM (Swift et al. 1991;
Easton 1994; FitzGerald et al. 1996; Vorechovsky et al.
1996).
The majority of mutations detected thus far in the
ATM gene in patients with AT are predicted to result in
protein truncation (Gilad et al. 1996; Concannon and
Gatti 1997). Western blot analyses of cell lines of pa-
tients with AT, with antibodies directed against ATM,
indicate that most of these truncating mutations are as-
sociated with an absence of detectable ATM protein
(Lakin et al. 1996; Stankovic et al. 1998). Some studies
have reported that patients with AT whose cells are ca-
pable of producing even modest amounts of ATM may
have distinct phenotypic features when compared with
those whose cells produce no detectable protein. One
class of mutations that has the potential to be “leaky”
and to allow for the production of at least some ATM
protein are those that affect the fidelity of splicing. In-
deed, two such mutations with effects on splicing of
ATM have been reported as being associated with either
a milder phenotype (McConville et al. 1996) or a variant
Table 1
ATM Primers
Primers Used Nucleotides Designation
For amplification of cDNA:
CAGAAGAGCACCTAGGCTAA 327–346 14F
CTGCCGTTATAATGCTTTAGG 1023–1003 14R
CGAGTGTGTGAATTAGGAGAT 748–778 AF3
CATTAAGCCTATGAAGAG 817–800 AR2
TGTTCTCTGTTTACTTCAG 500–685 ex8.2F
AGAATGATTTTGATCTTGTGC 1231–1211 11AR
GCTTACTTGGAGCCATAATTC 1517–1537 16F
GTGAACACCGGACAAGAGTT 2158–2139 16R
CGCTGTCTTCTGGGATTATC 2124–2093 17F
GTAGGTTCTAGCGTGCTAGA 2816–2797 17R
GTGTAACTACTGCTCAGACC 2720–2739 18F
GTTTCAGGGTTCTCAGCACT 3428–3409 18R
TGCATACTTGAAAGCTCAGGA 3366–3386 19F
TCAGTGCTCTGACTGGCACT 4091–4072 19R
AGACAGCCGTGACTTACTGTA 4508–4528 3F
CAGGATTATGAAGGTCCACTG 5145–5115 3R
TTGTCTTCGAAGATCC 4860–4845 R5
CAGTGGAGGCACAAAATGTGA 5445–5466 5F
CTGGCTTCCTTCTTCAAATGC 5948–5926 5R
CTCTATGCAGAAATCTATGCAG 5866–5887 6F
CTGGTTCCTTCTACTTCTTTGC 6368–6347 6R
CACTGCATATTCCTCCATGCTGC 6316–6304 R309
CAACCTGATTGTGTGGGATAG 6528–6507 B2
T7–ATGCAGTGGGACCATTGC 6319–6335 7F
GAGACTCCACAGCTAACTGAA 6866–6846 7R
GAAGTAGGTCTCCTTAGGGAA 7267–7287 9F
TTCTGACCATCTGAGGTCTCC 7855–7834 9R
TTGATGAGGATCGAACAGAGG 7780–7801 10F
CATTCAAGAACACCACTTCGC 8306–8285 10R
CACGGAAACTAGGAAGAGGAA 8226–8246 11F
CCCTGGTTTTCTCACAGCAT 8806–8787 11R
ATGAGCAGTCAGCAGAACTTG 8636–8656 12F
CTAAAGGCTGAATGAAAGGGTAAT 9209–9185 12R
Exon
Product Size
(bp)
For amplification of genomic DNA:
CCCCCTGTTATACCCAGTT 9F 318
TGAAGAAGCAAATTCAAAACAG 9R
TTTGTGGGGAGCTAGCAGTG 10F 262
TCTAAATGTGACATGACCTAC 10R
GTTTGTTAATGTGATGGAATA 12F 467
GTGTGTTTATCTGTAAGTCAG 12R
GTTCTTACAAAAGATAGAGTATAC 16.2F 329
TTCACAGGAATACATTTCATTC 16.2R
GTCCAAGATCAAAGTACACTG 17.2F 314
GTGACAGAGAAAGATCCTATC 17.2R
ATATTGGCCCTAATAGTAAAC 18F 292
CCTTATTTACAAAGATATTTCAAC 18.2R
CCGGCCTATGTTTATATACTT 21F 225
TTAACAGAACACATCAGTTAT 21R
TGGAGTTCAGTTGGGATTTTA 26F 304
TTCACAGTGACCTAAGGAAGC 26R
TGCTGAACCAAAGGACTTCT 32F 334
CACTCAAATCCTTCTAACAATA 32R
GTATGTTGAGTTTATGGCAGA 39F 376
ATCCATCTTTCTCTAGAACTG 39R
ACCAGAACCTTATAGCATAGT 40F 247
(continued)
Teraoka et al.: Splicing Mutations in ATM 1619
Table 1 (continued)
Primers Used Nucleotides Designation
Exon
Product Size
(bp)
TTCAGCCGATAGTTAACAAGT 40R
TAAGCAGTCACTACCATTGTA 41F 314
ATACCCTTATTGAGACAATGC 41R
GTATATGTATTCAGGAGCTTC 42F 238
ATGGCATCTGTACAGTGTCT 42R
CAGAACTGTATTTCAGAATCAT 43F 387
ACATAACTCCTTCATAAACAGT 43R
CCAAAGCTATTTTCACAATCTT 44F 262
TACTGAAATAACCTCAGCACT 44R
CTCTGGTTTTCTGTTGATATC 45F 236
CCCCATGAAGAATCAAGTC 45R
TTTATACATGTATATCTTAGGGTTCTG 46F 220
TTCAGAAAAGAAGCCATGACA 46R
CACTGCAGTATCTAGACAGT 54F 322
CTAGGAAAGACTGAATATCAC 54R
AATGTTGGGTAGTTCCTTATG 55F 308
GCTTTTGGATTACGTTTGTGA 55R
CCTTTGCTATTCTCAGATGACTCTGT 58F 290
GCATTATGAATATGGGCATGA 58R
TAGAAAGAGATGGAATCAGTG 61F 317
ATCTTGGTAGGCAAACAACAT 61R
AAAGTTCACATTCTAACTGGAA 62F 272
ATTACAGGTGCAAAGAACCAT 62R
TCCTGTTGTCAGTTTTTCAGA 65F 354
ACTTAAAGTATGTTGGCAGGT 65R
a Sequence is from Vorechovsky et al. (1996).
clinical presentation (Gilad et al. 1998), even in com-
pound heterozygotes.
There is suggestive evidence that splicing-related mu-
tations may be unusually frequent in AT. A recent survey
of published reports of ATM mutations included 115
alterations detected predominantly through the exami-
nation of ATM cDNA from patients with AT (Concan-
non and Gatti 1997; for updates, see the Ataxia-Tel-
angiectasia Mutations Database Website). A significant
fraction (45/115 [39.1%]) of these changes corre-
sponded to the loss of either exons or portions of exons,
presumably reflecting the presence of underlying splice-
site mutations. Unfortunately, for the majority (39/45)
of these ATM splicing alterations, only the observed ef-
fects in cDNA were reported, not the identity of specific
causative mutations. If it is assumed that such mutations
can be identified in the majority of cases, then the fre-
quency of splicing mutations in the ATM gene would be
substantially higher than that reported in surveys of
other human genetic disorders, in which ∼15% of point
mutations are found to affect mRNA splicing (Krawczak
et al. 1992; Ruttledge et al. 1996).
In the present study, we have sought confirmation of
the implied high frequency of splicing mutations in
ATM, through the study of an independent population
of patients with AT. Initial mutation screening was done
at the cDNA level, to identify any cell lines from patients
with altered splicing patterns. In all such cases, the un-
derlying mutation was then identified by sequencing of
genomic DNA. To evaluate the possible implications that
the different splicing mutations have for ATM expres-
sion, all cell lines of patients were tested for the pro-
duction of ATM, by western blotting. Where appropri-
ate, clinical features of specific patients were reexamined
in light of the mutation data.
Patients, Material, and Methods
Patients
Genomic DNA and mRNA were isolated, and cDNA
was synthesized, from B-lymphoblastoid cell lines pre-
viously established from patients with AT. Patients were
ascertained in Turkey, Poland, Italy, and the United
States. The clinical features for all patients were reviewed
by one of us (R.A.G.) and were found to be consistent
with the standard diagnostic criteria for AT. All clinical
diagnoses were confirmed by radiation-sensitivity testing
of cell lines by the colony-survival assay (Huo et al.
1994). Cell lines AT25RM, AT39RM, AT117LA, and
Table 2
Frequency of Mutations Associated with Splicing Defects in Patients with AT
AT Cell Line Genomic Mutationa Effect on cDNA Intron/Exon Codon Change
Codon
Numberb Status Consequence
Second
Mutant Allele
AT68LA 380delA 380delA 7 Frameshift 128 Heterozygote Truncation Unknown
AT113LA 748CrT 663del239 9 RrX 221 Heterozygote Exon 9 skipped, truncation Unknown
AT51LA 802CrT 663del239 9 QrX 268 Heterozygote Exon 9 skipped, truncation Unknown
AT134LA IVS91GrT 902del164 10 Frameshift 301 Heterozygote Exon 10 skipped, truncation 3802delG
AT139LA 1024delAAAG 1024delAAAG 10 Frameshift 343 Heterozygote Truncation Unknown
AT17LA 1180delGG 1180delGG 11 WrX 393 Heterozygote Truncation Unknown
AT81LA 1563delAG 1563delAG 12 Frameshift 522 Heterozygote Truncation 6100CrT
AT115LA 1563delAG 1563delAG 12 Frameshift 522 Homozygote Truncation )
AT39LA 1563delAG 1563delAG 12 Frameshift 522 Heterozygote Truncation 3382CrT
AT39RM IVS121GrT IVS12ins764 12 Frameshift 535 Homozygote Intron 12 retained, truncation )
AT54LA 2250GrA 2125del126 16 Silent 709 Heterozygote Exon 16 skipped 8266ArT
AT111LA IVS1610TrG IVS161ins9 17 Frameshift 750 Heterozygote Splice acceptor created, truncation 2809insCTAG
AT114LA IVS181GrA 2237del90 18 del30 792 Heterozygote Exon 18 skipped Unknown
AT25RM 2503insA 2503insA 19 Frameshift 835 Heterozygote Truncation Unknown
TAT50 2503insA 2503insA 19 Frameshift 835 Homozygote Truncation )
TAT49 IVS213insT 2839del83 21 Frameshift 946 Homozygote Exon 21 skipped, truncation )
AT84LA 3372CrG 3372CrG 25 YrX 1124 Heterozygote Truncation Unknown
AT142LA 3576GrA 3403del174 26 Silent 1135 Heterozygote Exon 26 skipped Unknown
TAT48 3576GrA 3403del174 26 Silent 1135 Homozygote Exon 26 skipped )
AT117LA 3576GrA 3403del 174 26 Silent 1135 Heterozygote Exon 26 skipped Unknown
AT136LA 3625delTT 3625delTT 27 Frameshift 1209 Heterozygote Truncation Unknown
AT36LA 3663GrA 3663GrA 27 WrX 1221 Heterozygote Truncation 1110delC
AT80LA 3802delG 3802delG 28 Frameshift 1268 Heterozygote Truncation Unknown
AT18RM 3894insT 3894insT 28 Frameshift 1299 Homozygote Truncation Unknown
AT137LA 4052delT 4052delT 29 Frameshift 1351 Heterozygote Truncation Unknown
AT140LA 4373delG 4373delG 31 Frameshift 1458 Heterozygote Truncation Unknown
AT11LA IVS3212ArG IVS321ins11 32 Frameshift 1479 Homozygote Splice acceptor created, truncation )
AT46LA 5290delC 5290delC 37 Frameshift 1764 Heterozygote Truncation Unknown
AT32LA IVS382ArC 5497del61 39 Frameshift 1832 Heterozygote Cryptic splice acceptor, truncation Unknown
TAT51 5623CrT 5623CrT 39 RrX 1875 Homozygote Truncation )
AT56LA IVS401126ArG IVS40ins137 40/41 Frameshift 1921 Heterozygote Cryptic splice sites, truncation Unknown
CAT13 IVS401126ArG IVS40ins137 40/41 Frameshift 1921 Heterozygote Cryptic splice sites, truncation Unknown
AT130LA 5932GrT 5919del88, 5932GrT 42 RrX 1973 Homozygote Exon 42 skipped, truncation )
AT63LA 5932GrT 5919del88, 5932GrT 42 RrX 1973 Heterozygote Exon 42 skipped, truncation 432insA
AT31LA 5971GrT 5919del88, 5971GrT 42 ErX 1991 Heterozygote Exon 42 skipped, truncation 7636del9
AT65LA 6095GrA 6007del89 43 Frameshift 2003 Heterozygote Exon 43 skipped, truncation 214GrT
AT138LA 6154GrA 6096del103 44 Frameshift 2032 Homozygote Exon 44 skipped, truncation )
AT127LA IVS451GrA 6007del326, 6347insAG, 6347ins78nt 45 Frameshift 2002 Homozygote Exon 43, 43–45 skipped,
truncation
)
AT30LA IVS461GrA 6348del105 46 del35 2176 Heterozygote Exon 46 skipped 6372insG
GM01525C 6404insTT 6404insTT 46 Frameshift 2136 Heterozygote Truncation Unknown
AT72LA IVS532ArC 7630del159 54 del53 2544 Heterozygote Exon 54 skipped 3085insA
AATV26 7705delGA 7705del GA 54 DrX 2569 Heterozygote Truncation Unknown
AT119LA 7865CrT 7864del64 55 Frameshift 2621 Homozygote Splice donor created, truncation )
AT121LA 8264delATAAG 8152del117 58 del39 2718 Heterozygote Exon 58 skipped 3485TrG
TAT45 IVS6014del27 8585del87 61 del29 2886 Homozygote Exon 61 skipped )
AT147LA IVS621GrA 8672del115 62 Frameshift 2891 Heterozygote Exon 62 skipped, truncation 6998insA
AT122LA IVS621GrA 8672del115 62 Frameshift 2891 Heterozygote Exon 62 skipped, truncation Unknown
AT73LA 8769insT 8769insT 62 Frameshift 2924 Heterozygote Truncation Unknown
AT34LA IVS641GrC 8988del13 65 Frameshift 3045 Heterozygote Cryptic splice acceptor, truncation Unknown
NOTE.—Mutations associated with splicing defects are enclosed in boxes.
a Numbering of nucleotides is based on the sequence reported by Savitsky et al. (1995b), which designates the first nucleotide of the initiating ATG codon as “1”; mutations are
designated according to the convention of Beaudet and Tsui (1993), as modified by Antonarakis (Recommendations for a Nomenclature System for Human Gene Mutations). Exon/
intron boundaries and numbering are as defined by Uziel et al. (1996), with introns numbered such that intron X follows exon X, 2 and 1 are the positions of the splice acceptor
AG, and 1 and 2 are the positions of the splice donor GT.
b In the case of a frameshift mutation, the codon given is that at which the predicted protein sequence diverges from the normal ATM protein sequence.
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AT18RMwere provided by one of us (L.C.). SV40-trans-
formed fibroblast cell lines LM217 and GM00637, from
two individuals with normal radiosensitivity, were ob-
tained from Dr. L. Kapp (University of California, San
Francisco). A B-lymphoblastoid cell line was established
from unaffected individual NAT2.
Primers
Primers used for the protein-truncation test (PTT) as-
say have been described by Telatar et al. (1998). Primers
used to amplify portions of the cDNA for SSCP and
sequence analyses, as well as primers used to amplify
exons from genomic DNA, are listed intable 1.
RNA Isolation, cDNA Synthesis, and the PTT
Specific methods for RNA isolation, cDNA synthesis,
and application of the PTT to ATM have been described
elsewhere (Telatar et al. 1996). Protein products from
the coupled in vitro transcription-translation reaction
were separated on 10%–20% gradient SDS-PAGE gels
for 5 h at 250 V.
SSCP
SSCP analyses (Orita et al. 1989) were done on both
cDNA and genomic DNA. PCR amplifications were
done in 50-ml reactions containing 200 mM each of
dCTP, dGTP, and dTTP (Boehringer Mannheim), 10
mM dATP (Boehringer Mannheim), 0.1–0.2 mCi of
[33P]-dATP (Amersham), 1 ng of each primer, 1.25 units
of Taq DNA polymerase (either AmpliTaq from Perkin-
Elmer/ABI or Taq polymerase from Boehringer Mann-
heim), and 50 ng of either cDNA or genomic DNA. The
amplification profile was 35 cycles of 30 s at 94C, 1
min at 55C, and 1 min at 72C, followed by a 7-min
extension at 72C. A 4-ml aliquot of the PCR product
was mixed with 10 ml of dye buffer (98% formamide,
10 mM EDTA pH 8, 0.05% bromophenol blue, and
0.05% xylene cyanol) and was heated for 5 min at 95C,
quick-cooled to 4C, and held on ice. Four microliters
of each sample was loaded on both a standard 0.5 #
MDE (mutation-detection enhancement [FMC]) gel and
a 0.5 # MDE gel supplemented with 5% glycerol. After
electrophoresis for 15 h at 7 W, gels were dried and
exposed to x-ray film for 24–48 h. Variant or wild-type
bands were cut from the gel, rehydrated in 20 ml of
distilled water, reamplified by PCR, and sequenced.
Sequencing
PCR reactions for direct sequencing of 50 ng of ge-
nomic DNA were done in 50-ml volumes containing 200
mM each of dATP, dCTP, dGTP, and dTTP (Boehringer
Mannheim), 0.3 mM of each primer, and 1.25 units of
Taq DNA polymerase (Perkin-Elmer/ABI or Boehringer
Mannheim) in PCR buffer. Amplification of cDNA for
sequencing was done as described for genomic DNA,
except that 1 ng of each primer was used. High Pure
columns (Boehringer Mannheim) were used to purify the
PCR products to be sequenced. Purified PCR products
(1–10 ml) were sequenced with an FS sequencing kit (Per-
kin-Elmer/ABI), were purified with Centri-sep columns
(Princeton Separations), and were electrophoresed on an
ABI 373 automated sequencer.
Western Blotting
Epstein-Barr virus–transformed lymphoblastoid cells
were grown in RPMI 1640 supplemented with 15% fetal
bovine serum, 100 mg of penicillin/ml, and 100 mg of
streptomycin/ml. Cell pellets of ∼1 # 106 cells were
washed twice with PBS (80 mM Na2HPO4, 15 mM
KH2PO4, 1.4 M NaCl, and 27 mM KCl) pH 7.4 and
then were lysed by sonication in 100 ml of cell lysis
solution (Analytical Chemiluminescent Laboratories)
containing 2 mg of aprotinin/ml and 550 mM phenyl-
methylsulfonylfluoride. During the procedure, the sam-
ples were kept on ice whenever possible. After sonica-
tion, the samples were centrifuged at 15,300g for 7 min
at 4C. The supernatants were recovered, and the protein
concentration was measured, by a modified Bradford
method (Bio-Rad). A total cell lysate of 25 mg was elec-
trophoresed on 6% SDS-polyacrylamide gels and was
blotted onto PVDF membranes (Bio-Rad) overnight at
4C. The efficiency of the transfer was verified by silver-
staining of the gel. Membranes were blocked with 10%
nonfat milk for 2 h. ATM protein was detected by a
monoclonal antibody generated against peptide
980–1512 in the leucine zipper and proline-rich region
of the ATM protein (Chen and Lee 1996). The primary
antibody was applied for 1 h. The membrane was then
washed six times with PBS-Tween 0.05%. Peroxidase-
linked anti-mouse Ig (Amersham) was applied for 30
min, and the membranes were washed six times with
PBS-T. Detection was done by the ECL system (Amer-
sham). Blotting of serial dilutions of lysates from normal
control cell line NAT2 was used to establish conditions
under which 10% of the normal level of ATM could be
reliably detected.
Results
Alterations in ATM cDNA were detected by either
SSCP or PTT in 49 cell lines derived from patients with
AT. Within these cell lines, a total of 62 mutations, cor-
responding to 75/98 (76%) of the disease chromosomes,
were identified in genomic DNA by both SSCP analysis
and DNA sequencing of exons (table 2). Some of the
cell lines are representative of founder-effect mutations
in specific ethnic groups, as described elsewhere (Telatar
et al. 1998). However, 32/62 (52%) of the mutations
reported here are novel. Of the 62 mutations, 30 (48%)
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Figure 1 SSCP of ATM subfragments from patients with AT and
from controls. In each of the panels A–F, cDNAs from AT cell lines
and from controls GM637 (lane N1) and LM217 (lane N2) are com-
pared. A, ATM7781-8305, including portions of exons 55–58. The
arrows in lane AT119LA indicate the two strands of the mutant tran-
script deleting 64 nucleotides at the end of exon 55. B, ATM1517-
2159, including portions of exons 12–16. The arrow in lane AT39RM
indicates the mutant transcript in which intron 12 was not removed.
C, ATM6319-6529, including portions of exons 45–47. In lane
AT127LA, band 1 represents a 72-nucleotide insertion from intron
45, band 2 represents an 80-nucleotide insertion from intron 45, and
bands in the region below band 3 all have AG inserted between exon
45 and exon 46. Bands in region 3a of the control lanes show the
slightly shifted positions of the wild-type transcripts. D, ATM4508-
5145, including portions of exons 32–36. In lane AT11LA, band 1
refers to the doublet representing the two strands of the mutant tran-
script in which 11 nucleotides of intron 32 were inserted. Bands near
3 and 4 represent transcripts that contained the 11 nucleotides of
intron 32 and skipped either exon 34 or exons 34 and 35, respectively.
Corresponding bands 3a and 4a of the control (lane N2) did not
contain the intron 32 insertion but skipped exon 34 or exons 34 and
35, respectively. Band 2 of lane AT11LA contained the intron 32 in-
sertion and had deletion of the first 25 nucleotides of exon 34. E,
ATM5866-6368, including portions of exons 41–45. The arrow in
lane AT130LA indicates a transcript lacking exon 42. The arrow in
the control (lane N2) indicates a transcript that had deletion of the
first 49 nucleotides of exon 45. F, ATM5445-5948, including exons
39–41. The arrows indicate the two strands of the mutant transcript
in which 137 nucleotides from the middle of intron 41 were inserted.
affected the accuracy of splicing of the ATM transcript.
In all cell lines in which mutations were identified, west-
ern blotting was used to determine whether any detect-
able normal-size ATM protein was produced.
Mutations in Canonical Splice Sites
Only 10 of the 30 ATM splicing mutations detected
in the present study altered either a conserved GT or
AG dinucleotide. Of the five mutations in the GT di-
nucleotide splice donor, three predictably resulted in
skipping of the adjacent exon, whereas the remaining
two mutations had unexpected effects (table 2).
In AT39RM, homozygous for the splice-donor sub-
stitution GTrTT in intron 12, two cDNA products were
visualized by SSCP, as shown in figure 1B and as dia-
grammed in figure 2B. The upper band in lane AT39RM
in figure 1B corresponds to an aberrantly spliced cDNA
from which intron 12 has not been removed. A small
amount of the correctly spliced cDNA is also seen (and
confirmed by direct sequencing of the cDNA), despite
the absence of an intact splice-donor sequence. Of the
30 splicing mutations detected in the present study, only
AT39RM exhibited intron retention. Retention of intron
12 is predicted to lead to a frameshift and truncation of
the protein. No ATM protein was detected by western
blotting in AT39RM, indicating that, although some
correctly spliced ATM transcript was produced in this
cell line, it did not lead to the accumulation of detectable
amounts of ATM protein (fig. 3).
In AT127LA, a homozygous mutation, GTrAT, of the
splice-donor sequence at the end of exon 45
(IVS451GrA) resulted in the production of multiple
incorrectly spliced transcripts identified in cDNA (see
the numbered bands in fig. 1C, lane AT127LA). These
transcripts corresponded to an insertion of 72 nucleo-
tides from intron 45, an insertion of 80 nucleotides, an
insertion of 2 nucleotides between exons 45 and 46, and
a fourth species (data not shown) that had a deletion of
exons 43–45. No normally spliced transcripts (shown in
band 3a in fig. 1C, lanes N1 and N2) were detected in
AT127LA, and, as expected, no ATM protein could be
detected in cell lysates by western blotting (fig. 3).
The effects of mutations at the conserved AG dinu-
cleotide of the splice acceptor were similarly diverse.
Two mutations, IVS9-1GrT (in AT134LA) and IVS53-
2ArC (in AT72LA), resulted in skipping of exons 10
and 54, respectively (table 2). However, two other sim-
ilar mutations, IVS64-1GrC (in AT34LA) and IVS38-
2ArC (in AT32LA), each resulted in the activation of
cryptic splice sites (table 2).
Mutations at Positions Flanking Canonical Splice–Site
Sequences
Three mutations were identified that altered nucleo-
tides at the less-conserved positions (Padgett et al. 1986;
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Figure 2 Effects of ATM splice mutations. A, Mutation 7865CrT, which creates a splice donor (GT) within exon 55, resulting in the
deletion of 64 nucleotides at the end of the exon. Arrows indicate sites joined by splicing on this mutant allele. B, Mutation IVS121GrT of
the splice donor in intron 12, which abolishes normal splicing of intron 12. Intron 13 is correctly spliced, as indicated by arrows. C,Mutation
IVS 32-12ArG, which creates a splice acceptor (AG) in intron 32, resulting in the inclusion of 11 nucleotides of intron 32 in the transcript.
No mutations were detected in the splice sites of exon 34 or exon 35, but either one or both of these exons were deleted in some of the
transcripts from AT11LA, as indicated by arrows, suggesting that variant splicing occurred.
Krawczak et al. 1992) flanking the invariant GT dinu-
cleotide of the splice donor. Two patients (TAT48 and
AT117LA) had a 3576GrA mutation altering the last
nucleotide of exon 26, and another patient (AT54LA)
had an analogous mutation affecting the last nucleotide
of exon 16 (2250GrA) (table 2). In all three cases, the
nucleotide substitution itself is silent with respect to the
amino acid sequence. Patient TAT48 is homozygous for
the 3576GrA mutation and thus is particularly illus-
trative with regard to the effect that such a substitution
has at the last nucleotide of this particular exon. The
only transcript detected in this cell line had exon 26
deleted (fig. 4), as shown by SSCP and as confirmed by
direct sequencing, indicating that the GrA substitution
was sufficient to completely disrupt normal splicing. De-
letion of exon 26 should result in a transcript that, if
translated, would leave the reading frame of the ATM
protein intact but that would eliminate 58 amino acids.
Nevertheless, no ATM protein of normal or altered mo-
lecular weight was detected in patient TAT48 by western
blotting (fig. 3).
The mutation IVS213insT in patient TAT49 high-
lights the significance of two other, less well-conserved
positions in the consensus splice site. Patient TAT49 is
homozygous for the insertion of T at the 3 position,
leading to the altered splice-donor sequence TC F
GTTAAGAA (position3 is underlined, and the vertical
bar denotes the intron/exon boundary), compared with
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Figure 3 Western blots of proteins from cell lysates for seven
patients with AT and for a control. ATM protein was detected with
a monoclonal antibody generated against peptide 980-1512 in the
leucine zipper and proline-rich region of the ATM protein (Chen and
Lee 1996). Control NAT2 is represented in lane 1. b-Actin antibody
provides an internal standard for the amount of protein per lane. Lanes
1–3, 5, and 6 were taken from one blot, whereas lanes 4, 7, and 8
represent separate experiments. In all cases, ATM was readily detected
in the control.
Figure 4 A, SSCP of ATM cDNA subfragments demonstrating
absence of wild- type transcript in homozygous ATM patients TAT48
and TAT49. Control LM217 is represented in lane N2. Nucleotide
positions of the subfragments are indicated at the top of the figure.
B, Diagrams of the splicing consensus site defects in the genomic DNA
of the patients with AT that led to the cDNA SSCP pattern in 3A.
the wild-type sequence TC F GTAAGAAA. The muta-
tion in patient TAT49 disrupts the consensus sequence,
placing the rarely used residue T (2%) at the3 position
and the rarely used residue A (7%) at the 5 position.
Shapiro and Senapathy (1987) have described a scor-
ing system for calculation of the likelihood that a par-
ticular splice-donor or -acceptor sequence as a whole
would be functional. In their rating of 5′ splice-donor
sequences, no functional donor sequences scored !60 on
this scale. The mutation identified in patient TAT49 re-
duces the score of this splice-donor sequence from 72.8
to 49.3, suggesting that it is unlikely to be functional.
The consequence of this mutation was that only ATM
transcripts lacking exon 21 were detected by either SSCP
or sequencing of cDNA from this cell line (fig. 4). West-
ern blotting of lymphoblastoid-cell lysates from patient
TAT49 failed to detect any ATM protein (data not
shown).
Mutations Creating Novel Splice Sites
Three mutations were identified that created novel
splice sites: IVS32-12ArG in AT11LA, 7865CrT in
AT119LA, and IVS16-10TrG in AT111LA (table 2). In
two of these cases, AT11LA and AT119LA, the families
were consanguineous, and the mutations were homo-
zygous, simplifying the interpretation of their effects.
The IVS32-12ArG mutation created a new splice-ac-
ceptor dinucleotide site, 11 nucleotides 5′ of the normally
used splice acceptor for exon 33 (diagrammed in fig.
2C). This mutated sequence scored high (91.6) when its
potential as a splice acceptor was calculated (Shapiro
and Senapathy 1987). SSCP analysis of cDNA from this
region revealed several different transcripts (fig. 1D,
bands 1–4), all of which contain an insertion of the last
11 nucleotides of intron 32. This insertion results in a
frameshift predicted to cause premature truncation of
the protein. The new splice-acceptor site created by the
mutation was used exclusively, despite the continued
presence of the normal splice acceptor downstream. The
proximity of the normal and mutant splice sites suggests
that preference for the mutant site may arise from a
suppressing effect on the normal site. In creating a novel
splice acceptor, the mutation significantly reduces the
splice site–potential score for the wild-type acceptor. No
ATM protein was detected in AT11LA by western blot-
ting, consistent with the exclusive production of mutant
transcripts observed by SSCP (fig. 3).
Although two of the smaller ATM transcripts detected
in AT11LA represent the skipping of either exon 34 or
exons 34 and 35 (fig. 1D, bands 3 and 4, respectively),
control cell line LM217 (fig. 1D, lane N2) also produced
minor transcripts with deletion of either exon 34 (fig.
1D, lane N2, band 3a) or exons 34 and 35 (fig. 1D,
lane N2, band 4a), albeit without the inclusion of 11
extra nucleotides from intron 32. On the SSCP gel, an
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Figure 5 Missplicing of exon 9, in the absence of splice-site
mutations. Shown are nested-PCR products of ATM nucleotide po-
sitions 500–1191 from cDNAs of AT113LA, AT140LA, and AT51LA
and from control LM217 (lane N2). Patients AT113LA and AT51LA
are heterozygous for the exon 9 nonsense mutations 748CrT and
802CrT, respectively. AT140LA and control LM217 have nomutation
in either exon 9 or the flanking splice consensus sites. All cell lines
produce varying amounts of transcripts with exon 9 deleted. The 123-
bp ladder marker is shown in lane M.
additional faint band present in both the sample from
AT11LA and that from control LM217 (fig. 1D, lane
AT11LA, band 2) represents a transcript with the first
25 nucleotides of exon 34 deleted. Because no corre-
sponding genomic mutations were detected for any of
these three deleted products, and because they were
found in controls, they are most likely rare, aberrantly
spliced transcripts that are normally present and not the
consequence of a mutation.
Patient AT119LA is homozygous for a CrT mutation
at nucleotide 7865, creating a new splice-donor site
within exon 55 (diagrammed in fig. 2A). Despite the
continued presence of the normal splice-donor site, the
new site was used exclusively, resulting in the deletion
of 64 nucleotides at the end of the exon. Unlike the
mutation in AT11LA, the novel splice site created by the
mutation in AT119LA does not have an improved score
for its potential as a splice site. In figure 1A, the SSCP
pattern for this region in AT119LA displayed only the
aberrantly spliced transcript. Sequencing revealed that
the two major SSCP bands had 64 nucleotides deleted
in exon 55. No ATM protein was detected in this cell
line by western blotting (fig. 3).
Nonsense and Missense Mutations with Indirect Effects
on Splicing
Two distinct nonsense mutations in exon 9 were de-
tected in patients AT113LA (748CrT) and AT51LA
(802CrT), both of whom are compound heterozygotes.
Despite the fact that neither mutation altered an existing
splice site or created a novel site, these cell lines produced
comparable amounts of both properly spliced and exon
9–deleted transcripts (fig. 5). No additional mutations
were detected in any splice-consensus sites within exon
9, including purine-rich or AC-rich splicing-enhancer se-
quences (reviewed by Cooper and Mattox 1997) or the
∼50 bp of flanking sequences to either side. The deletion
of exon 9 was also noted in two other cDNAs—that of
AT140LA and that of control LM217 (fig. 5)—although
in very small amounts; neither had mutations in either
exon 9 or flanking introns.
Patient AT130LA is homozygous for a nonsense mu-
tation in exon 42, resulting from the mutation
5932GrT. As shown in figure 1E, AT130LA produced
a properly spliced transcript comparable in amount to
that produced in control LM217 (fig. 1E, lane N2); how-
ever, AT130LA also produced a unique transcript lack-
ing exon 42 (indicated by the arrow in fig. 1E, lane N2).
A faint band with comparable migration to the exon
42–deleted band in AT130LA was also detected in the
control cell line (indicated by the diagonal arrow in fig.
1E, lane N2). This band was isolated, sequenced, and
found to represent a transcript lacking the first 49 nu-
cleotides of exon 45, apparently a minor, alternatively
spliced species in normal cells.
AT138LA produced only ATM transcripts with exon
44 deleted. No other evidence of a mutation elsewhere
in the gene was detected by PTT. Sequencing of exons
43–46 and flanking intronic sequences revealed only a
single mutation, 6154GrA, within exon 44, resulting in
a nonconservative amino acid substitution, 2032ErK.
Deletion of exon 44 results in a frameshift. Western blot-
ting of lysates from this cell line failed to reveal any
ATM protein (data not shown).
Variant Splicing Not Associated with Mutations
During the course of screening ATM cDNA subfrag-
ments for mutations, several regions were encountered
where transcripts had exon(s) or portions of exons de-
leted but for which no underlying genomic mutations
within either the exon or the flanking splice sites could
be found; for example, PTT assays revealed aberrantly
migrating bands in the region encompassing portions of
exons 10–12 in patients AT115LA, AT81LA, and
AT139LA. The cDNA from these patients contained
substantial amounts of products lacking exon 11, as
shown in the SSCP assay in figure 6 and as confirmed
by isolation and sequencing of the shortened products.
However, no splice-site mutations were detected flanking
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Figure 6 Variant splicing of ATM transcripts, in the absence of
mutations. Nested PCR of ATM nucleotides 327–870 from three pa-
tients with AT and from control LM217 (lane N2) show an alterna-
tively spliced transcript missing the first 22 nucleotides of exon 8.
Nested PCR of ATM nucleotides 947–1392 from three patients and
the control LM217 (N2) show an alternatively spliced transcript with
exon 11 deleted. Patient AT139LA had bands below the wild-type and
exon 11–deleted bands, representing its mutation in exon 10, as
1024delAAAG. Patients AT115LA and AT81LA are homozygous and
heterozygous, respectively, for an exon 12 mutation (1563delAG) not
contained in the amplified fragment.
exon 11 in the genomic DNA of these individuals. Ex-
amination of surrounding exons did reveal truncating
mutations in three of these patients: AT115LA and
AT81LA had a deletion of two nucleotides in exon 12,
and AT139LA had a deletion of four nucleotides in exon
10 (table 2). Transcripts lacking exon 11 were also read-
ily detected in control LM217 (fig. 6), again without any
underlying mutation being detected.
Amplified cDNAs from cell lines of patients with AT
that had truncated fragments in the PTT assay for the
region containing exons 7–10 also displayed a wide va-
riety of bands on SSCP gels (fig. 6). The cDNA from
patients AT45LA, AT51LA, AT84LA, AT113LA,
AT134LA, and AT140LA contained a product lacking
the first 22 nucleotides of exon 8. The presence of an
AG dinucleotide at the end of the 22 deleted nucleotides
is consistent with the use of a cryptic splice-acceptor
sequence. However, there was no mutation of the orig-
inal splice acceptor in the genomic DNA of any of the
individuals. Moreover, cDNA from control LM217 also
contained the 22 nucleotide–deleted product (fig. 6).
Other examples of cryptic-splice-site utilization were
seen in minor transcripts from a number of patients with
AT and from controls. These include the deletion of the
first 41 nucleotides of exon 15 (in AT117LA), the de-
letion of the first 86 nucleotides of exon 14 (in AT63LA),
and either the skipping of exons 11, 34, and/or 35 or
deletion of the first 19 nucleotides of exon 17 (in control
LM217). In all these cases, no splice-site mutations were
detected in the genomic DNA; however, the sequences
at the end of the cDNA deletions indicated that cryptic
splice sites had been used.
Discussion
Most studies of ATM mutations suggest that a high
percentage are inactivating mutations resulting in pro-
tein truncation and the production of little or no ATM
protein. In the ATM gene, with its large complement of
exons, splice sites represent a sizable target formutations
that would have severe effects on the protein product.
In a previous review of AT mutations (Concannon and
Gatti 1997), we noted that a high percentage (39%) of
alterations detected in ATM cDNA from patients with
AT reflected the loss of one or more exons, a result
consistent with this hypothesis. However, because the
majority of published studies have examined only cDNA
transcripts ofATM, there is a potential for ascertainment
bias in the reported number of splicing mutations in the
ATM gene. The loss of an entire exon is easily apparent
by visual examination of enzymatically amplified cDNA
products, regardless of what mutation-screening tech-
nique is being used. Therefore, exon skipping should be
among the defects easiest to identify in cDNA. Further-
more, in cases in which an underlying genomic mutation
has not been identified, exon skipping may simply reflect
low-level missplicing that occurs normally but is more
apparent in AT cell lines in which overallATM transcript
levels may be reduced.
In the set of 62ATMmutations reported in the present
study, a significant fraction (30/62 [48%]) affected splic-
ing of the ATM transcript. These results are consistent
with our earlier suggestion that splicing-related muta-
tions are unusually frequent in AT. The canonical GT
and AG dinucleotides that flank most mammalian exons
are frequent targets of mutations that affect splicing
(59% of mutations compiled by Krawczak et al. [1992]
and 71% of mutations compiled by Schwarze et al.
[1997]). In contrast, the majority of mutations effecting
splicing that were detected in the present study did not
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directly alter the canonical AG or GT exon-flanking din-
ucleotides but, instead, either targeted less-conserved se-
quences surrounding splice junctions or created novel
splice sites. Several other instances of exon skipping that
were observed in ATM were not associated with any
detectable underlying mutation, suggesting that somede-
gree of caution is necessary in the interpretation of such
alterations when they are observed only in cDNA.
Two different mutations detected in the present study,
3576GrA and IVS401126ArG, have previously been
described (by Gilad et al. [1998] and McConville et al.
[1996], respectively) in patients reported to exhibit an
atypical clinical course of AT. The mutation 3576GrA
in patient TAT48 resulted in exclusive production of
transcripts with exon 26 deleted. Deletion of exon 26
does not alter the translational reading frame for the
ATM protein. No normal-length transcripts were de-
tected, despite the sensitivity of PCR as an assay. If an
exon 26–deleted transcript were to be translated into a
stable protein, it would be only 58 amino acids (∼2%
of the total length) shorter than normal. On an SDS-
PAGE gel, which is commonly used for protein assays,
such a protein would be indistinguishable from the nor-
mal one. Gilad et al. (1998) have described several cell
lines that are homozygous for this mutation and inwhich
they could detect a low level of ATM protein (∼5% of
the level in controls). In the present study, no ATM pro-
tein was detected in patient TAT48. The discrepancy
between our results and those of Gilad et al. may be due
to differences in experimental conditions. However, in
light of the absence, in patient TAT48, of any transcripts
containing exon 26, only ATM protein with an internal
deletion of 58 amino acids (encoded by exon 26) could
be produced. If such a shortened protein is produced in
these cells, it is unclear whether it would be functional
or have any significant impact on the clinical phenotype.
An additional patient in the present study, AT117LA,
was heterozygous for the 3576GrA mutation and had
clinical features consistent with the AT variant disorder
ATFresno. ATFresno encompasses all of the features of AT
but includes microcephaly and mental retardation in the
phenotype (Curry et al. 1989). AT117LA is only the
second patient with ATFresno who has been screened for
ATM mutations. The other previously characterized AT-
Fresno patient, AT25LA, is homozygous for a splice-site
mutation in intron 33 (Gilad et al. 1998). The 3576GrA
mutation in AT117LA has been observed in several pa-
tients with AT who have classic phenotypes, including
two patients (AT142LA and TAT48) in the present study.
The IVS332TrC mutation in AT25LA is unique, but
there are several patients with AT who have a very sim-
ilar IVS332TrA mutation, one of whom is homozy-
gous. Neither AT117LA nor AT25LA produces detect-
able levels of ATM protein. Thus, the variant phenotype
observed in these patients with ATFresno seems unlikely
to result from the nature of their ATM mutations alone,
given (1) the occurrence of these same mutations in typ-
ical patients with AT and (2) the fact that absence of
detectable ATM protein is also frequent among classic
patients with AT. The ATFresno phenotype may result in-
stead from epistatic effects of other, as yet unidentified
genes.
The IVS401126ArG mutation, reported to be as-
sociated with a milder clinical course of AT (McConville
et al. 1996), was detected in two patients (AT56LA and
CAT13; fig. 1F) in the present study and in one patient
(AT13LA) from a previously published study (Wright et
al. 1996), all of whom are compound heterozygotes. In
AT56LA, the two ATM alleles could be distinguished
because of a nearby common polymorphism (5557G/A
in exon 39; Dork et al. 1997). The allele containing the
IVS401126ArG mutation produced both wild-type
and mutated (insertion of 137 nucleotides) transcripts
in comparable, albeit low, amounts. However, no ATM
protein was detected in any of these cell lines (see fig.
3, lanes AT13LA and AT56LA), raising concerns as to
whether the production of this small amount of normal
transcript could significantly affect the phenotype of
these patients.
All 12 patients whom McConville et al. (1996) de-
scribed as having a milder clinical phenotype were com-
pound heterozygotes for the IVS401126ArG muta-
tion, as were patients AT56LA, CAT13, and AT13LA.
However, in 8 (67%) of these 12 patients, the ages at
onset of ataxia were 1–3 years, which is quite charac-
teristic of classic AT. The age at onset of ataxia in the
three affected siblings in the family of patient AT56LA
were also characteristic of AT: 8 mo, 18 mo, and 3 years.
In the family of patient AT13LA, the ages at onset were
5 years and 6 years for the two affected siblings.
McConville et al. (1996) also suggest a decreased fre-
quency of cancer in IVS401126ArG patients. This is
corroborated in the families of patients AT56LA and
AT13LA; in the latter, the affected siblings lived to ages
40 and 44 years without cancer. Thus, some aspects of
the milder phenotype reported in conjunction with the
IVS401126ArG mutation appear to recur in separate
patient groups. However, identification and clinical char-
acterization of additional patients with this mutation
will be necessary to clarify the exact relationship be-
tween phenotype and genotype.
Twelve (∼20%) of the patients in the present study
had mutations that resulted in nonsense premature-ter-
mination codons (PTCs), and in five of these patients
the PTCs were associated with some degree of deletion
of the exon containing them. All prokaryotic and eu-
karyotic cells that have been examined appear to have
mechanisms to degrade RNAs that harbor PTCs (Ma-
quat 1995, 1996). However, in cell lines from patients
with AT who are compound heterozygotes for a PTC
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mutation and a second unrelated mutation, equimolar
amounts of mRNA from PTC-containing alleles and
from the other allele are detected by reverse transcrip-
tase–PCR. The observed skipping of the ATM exon con-
taining the PTC appears to be a specific event, one that
is not associated with general degradation of transcripts
containing the PTC. PTC mutations that lead to specific
deletion of the exons containing them have also been
reported for BRCA1 (Mazoyer et al. 1998), the gene for
fibrillin (Dietz et al. 1993), CFTR (Hull et al. 1994), the
gene for mouse immunoglobulin k (Aoufouchi et al.
1996), and the gene formouse urinary protein (Belgrader
and Maquat 1994), among others. Reports that even
missense mutations can cause the deletion of exons con-
taining them (Belgrader and Maquat 1994; Liu et al.
1997) suggest that additional mechanisms, not depen-
dent on the presence of PTCs, may lead to effects on
splicing.
In the present study, one patient (AT138LA) had only
ATM transcripts with exon 44 deleted. Examination of
the genomic sequence in and around exon 44 revealed
only a single homozygous change, a GrA substitution
at position 6154, a position that is conserved in the
mouse ATM sequence. The resulting nonconservative
amino acid substitution, ErK, may alter protein struc-
ture or function, but it would not necessarily be expected
to terminate protein translation. Despite the observed
missplicing of exon 44, this mutation does not affect any
known splicing-control motif (including exonic splicing-
enhancer sequences; see review by Cooper and Mattox
[1997]). Hoffmeyer et al. (1998) have suggested that
particular PTCs, while not altering any established
splice-consensus sites, may cause defective splicing by
inducing a significant alteration in the secondary struc-
ture of the transcript, disrupting the formation of the
spliceosome. In a study of mutations in the HPRT gene,
Steingrimmsdottir et al. (1992) noted that all of seven
missense mutations that were associated with splicing
defects disrupted base pairing in stem-loop structures in
the predicted secondary structure of the corresponding
RNA. In light of the observations, in AT138LA, of both
a deletion of exon 44 and the 6154GrA missense mu-
tation, it seems reasonable to postulate that this missense
mutation may also cause defective splicing, by a similar
mechanism. When the RNA secondary structure of exon
44 was predicted by the program mfold, position 6154
was projected to lie at the base of a stem-loop structure.
The GrA mutation in AT138LA disrupts the GC base
pair at this site, resulting in a predicted destabilization
of a portion of the stem structure, a result consistent
with the model of Steingrimmsdottir et al. (1992)
For some regions of ATM, exon-deleted transcripts
have been detected even in controls. Although multiple,
differentially spliced transcripts have been described for
ATM, all were due to alternative splicing in the untran-
slated regions, not in the coding exons (Savitsky et al.
1997). Because the ATM mRNA is large, and because
mutation screening involves amplification of only por-
tions of the mRNA at a time, we cannot rule out the
possibility that alternatively spliced products described
in the present study are derived from either nonfunc-
tional, truncated transcripts or transcripts in the process
of being degraded. However, regardless of whether they
play a functional role, the fact that these exon-deleted
products are easily detected in significant amounts in
standard mutation-screening assays indicates that cau-
tion should be applied in the interpretation of observed
cases of exon skipping in ATM cDNA, until a credible
underlying mutation in genomic DNA can be identified.
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